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The Pruritus Receptor Unit: A Target 
for Novel Therapies
Gil Yosipovitch1
Although the role of prostanoids in itch was actively studied a decade ago, 
interest in this area has waned in recent years. Andoh et al. (2007, this issue) 
demonstrate that the prostanoid thromboxane A2 elicits scratching through its 
TP receptor. Identification of new itch mediators and their respective receptors 
within the skin will undoubtedly be the focus of future drug development for 
this distressing symptom.
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A unique feature of itch is that it is 
restricted to the skin and occasion-
ally the adjoining mucosa, such as the 
conjuctiva. Itch sensation emanates 
from the activity of nerve fibers in the 
epidermis and upper layers of der-
mis. Although a specific receptor for 
itch has not yet been identified within 
these layers, the following data support 
this notion: (i) removal of the epider-
mis abolishes perception of pruritus, 
(ii) inflammation in the reticular dermis 
and subcutaneous fat, such as that seen 
in panniculitis and cellulites, frequently 
causes pain but not itch (it is assumed 
that nerve fibers located in deeper lay-
ers of the reticular dermis and subcu-
taneous fat do not transmit pruritus, 
(iii) light microscopy using specific 
markers for nerve fibers such as protein 
gene product 9.5 and ultrastructural 
studies of human skin have demonstrat-
ed the existence of intraepidermal nerve 
fibers with “free” nonspecialized nerve 
endings extending into the stratum 
granulosum, and these fibers are over-
expressed in itchy dermatoses. Many of 
these fibers stain positively for neuro-
peptides believed to be itch mediators, 
such as substance P, somatostatin, vaso-
active intestinal polypeptide, and neu-
ropeptide Y, suggesting that pruritus is 
transmitted in the epidermis by C fibers.
C fibers are primary afferent noci-
ceptors. Moreover, keratinocytes 
express a variety of neural mediators 
and receptors, all of which appear to 
be involved in itch sensation. These 
include opioids, proteases, substance 
P, nerve growth factor, neurotrophin 
4, and endocannabinoids, and their 
respective receptors, including μ- and 
κ-opioid receptors, PAR-2, vanilloid 
receptors, TRPV ion channels, TrkA, 
TrkB, and cannabinoid receptors 1 and 
2. Keratinocytes also have voltage-gated 
ATP channels and adenosine similar to 
C nerve fibers (Steinhoff et al., 2006). 
Because these channels have a role in 
pain, it is possible that keratinocytes 
may act as itch receptors in specific 
skin inflammatory conditions.
Histamine has been considered the 
archetypal itch mediator in inflamma-
tory skin disease for decades. However, 
the mechanism by which histamine 
induces itch transmission via nerve 
fibers was unclear until recently. Han 
et al. (2006) demonstrated that phos-
pholipase Cβ3, a molecule that links 
G protein–coupled receptors to an 
intracellular signaling network, medi-
ates the scratching response activated 
by the histamine H1 receptor on C 
nerve fibers. However, the role of his-
tamine in most types of chronic itch is 
minimal, as attested by the lack of effi-
cacy of antihistamines in alleviating 
pruritus. A recent study suggests that 
histamine H4 agonists and histamine 
H3 antagonists induce itch by a G pro-
tein–coupled receptor that mobilizes 
Ca2+ in eosinophils. In addition, the his-
tamine H4 receptor is found in human 
skin mast cells (Lippert et al., 2004). 
Moreover, histamine and a selective 
histamine H4 receptor agonist caused 
a scratching response in mice, which 
was almost completely attenuated in 
histamine H4 receptor knockout mice 
or by pretreatment with a selective 
histamine H4 receptor antagonist. The 
inhibitory effect of the histamine H4 
receptor antagonist was greater than 
that observed with histamine H1 recep-
tor antagonists (Dunford et al., 2007). 
Histamine H4 receptor-mediated pruri-
tus has been shown to be independent 
of mast cells or other hematopoietic 
cells, suggesting that this itch may be 
mediated by peripheral nerve fibers in 
the skin.
The role of proteases in the pruritus 
of atopic eczema has been clearly dem-
onstrated. Proteases, such as tryptase, 
activate proteinase activated receptor-2 
(PAR2) localized in C nerve fiber termi-
nals in the skin (Steinhoff et al., 2006). 
The importance of epidermal serine 
proteases in eliciting itch has been fur-
ther demonstrated in a mouse model, 
which showed that overexpression of 
serine protease caused severe itch and 
scratching. Proteinase activity can also 
be found in common allergens and 
staphylococcal skin infections, both of 
which aggravate atopic dermatitis and 
itch. Recent studies demonstrated that 
serine proteases also impair the stra-
tum corneum barrier function; this may 
further explain why impaired stratum 
corneum barrier function in dry skin 
induces itch (Nakamura et al., 2006).
For more than a decade, the per-
ception of pruritus has been known to 
be modified by endogenous opiates 
via central opioid receptors. A recent 
study illustrated that µ- and κ-opioid 
receptors are expressed in keratino-
cytes and in peripheral nerve endings 
in the skin. In particular, induction of 
dry skin dermatitis in μ-opioid-receptor 
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The scratching response 
was abolished by 
defi ciency of TP 
receptor and TP 
receptor antagonist.
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knockout mice had a significant impact 
on increasing density of epidermal 
nerve fibers and resulted in significantly 
less scratching behavior in comparison 
with wild-type mice. The inflammatory 
infiltrate composed of mast cells and T-
cell lymphocytes did not correlate with 
the alterations in opioid receptors, sug-
gesting that opioid can exert itch with-
out inflammation or mast cell activation, 
as was previously thought (Bigliardi-Qi 
et al., 2005). Nociceptin, the endog-
enous peptide ligand for opioid recep-
tor-like-1 (ORL1) receptor, is another 
opioid receptor involved in itch. Recent 
data using a mouse model suggest that 
nociceptin acts on the ORL1 receptor 
expressed on keratinocytes to produce 
leukotriene B4, which induces scratch-
ing (Andoh et al., 2004).
Although the role of prostanoids in 
itch was actively studied a decade ago, 
it has become somewhat neglected 
over recent years. Prostaglandins were 
initially found to enhance histamine-
induced itch in the skin (Hagermark et 
al., 1977). Prostaglandins are the prod-
ucts of transformation of the essential 
fatty acid arachidonic acid by cyclo-
oxygenase 1 or cyclo-oxygenase-2. It 
appears that only pruritic neurons that 
display lasting activation following his-
tamine are excited by PGE2, and mech-
anosensitive fibers are unresponsive 
to both histamine and PGE2. PGE2 has 
also been shown to have a direct low-
level pruritogenic effect without induc-
ing protein extravasation in healthy and 
atopic dermatitis patients; this suggests 
that prostanoids’ peripheral action is 
not solely via histamine and that pros-
tanoids may potentiate pruritus via a 
nonspecific effect on nerve fibers.
In this issue, Andoh et al. (2007) 
add significantly to our knowledge of 
the involvement of thromboxane A2 
(TXA2), a prostanoid synthesized from 
prostanoid H2 via cyclo-oxygenase and 
TXA synthetase, in cutaneous itch. They 
beautifully demonstrate that TXA2 elic-
its scratching through its TP receptor—a 
G protein–coupled receptor located 
in both keratinocytes and skin nerve 
fibers. The scratching response was 
abolished by deficiency of TP receptor 
and TP receptor antagonist. The TXA2 
agonist caused membrane-cell depo-
larization, which was short lived in pri-
mary sensory neurons, but the scratch-
ing response lasted around 50 minutes, 
which coincided with depolarization in 
keratinocytes. TXA2 may be produced 
by keratinocytes and acts on keratino-
cytes as an autocrine factor, releasing 
other itch mediators such as leukotri-
ene B4 and nociceptin, as well as itch 
enhancers, such as nitric oxide.
Oral administration of aspirin, a 
cyclo-oxygenase inhibitor, does not 
ameliorate pruritus except in polycythe-
mia vera; however, topical salicylates 
and topical aspirin have been demon-
strated to significantly reduce pruritus 
in patients with chronic localized itch 
(Yosipovitch et al., 2001). Do other 
prostanoids have a role in pruritus? A 
recent study illustrated that prostaglan-
din D2 (PGD2) is a mediator that inhibits 
itching in NC/NG mice with atopic-like 
dermatitis and that repeated scratching 
in this model further reduced levels of 
PGD2, suggesting that the vicious itch–
scratch cycle is associated with low 
levels of PGD2 (Sugimoto et al., 2007). 
The role of other prostanoids and eico-
sanoids, including leukotrienes and 
12-hydroxyeicosatetraenoic acid (12-
HETE), in the pathogenesis of pruritus is 
unclear. We previously demonstrated in 
rats that prostanoids secreted from the 
bone marrow have a diurnal rhythm. 
This could possibly explain why the 
bone pain of metastatic cancer, as well 
as pruritus, irrespective of underlying 
cause, is frequently exacerbated during 
the night (Yosipovitch et al., 1995).
Multiple other neuromediators are 
involved in both itch and pain, such 
as neurotrophins and transient recep-
tor potential activators. The prototype 
neurotrophic factor is NGF, which was 
found to be elevated in atopic eczema 
(Toyoda et al., 2002). The prototype 
transient receptor potential activator 
is TRPV1, a vanilloid receptor located 
both on C nerve fibers and on kera-
tinocytes. This receptor is activated 
by capsaicin as well as endogenous 
substances, such as cannabinoids, 
prostaglandins, and various neuro-
trophins. Cannabinoid receptors CB1 
and CB2 are located in the epidermis; 
recently, a cannabinoid agonist was 
shown to inhibit histamine-induced 
itch (Rukweid et al., 2004). In addition, 
topical agonists of cannabinoid recep-
tors were shown to have an antipruritic 
effect in atopic eczema and uremic 
pruritus (Stander et al., 2006).
The role of cytokines, such as inter-
leukin (IL)-2, in pruritus is well docu-
mented. This has been the basis for 
the use of immunomodulators, such 
as tacrolimus and pimecrolimus. These 
topical calcineurin inhibitors inhibit 
the production of IL-2 and have been 
shown to inhibit itch. IL-31 is a newly 
discovered cytokine produced by 
T helper 2 cells. Keratinocytes express 
the IL-31 receptor, and, in a recent 
study using a transgenic mouse model, 
overexpression of this cytokine led 
to severe scratching and dermatitis 
(Sonkoly et al., 2006).
The identification of new neuropep-
tides and their respective receptors in 
the skin that are specific to itch trans-
mission will eventually form targets 
for novel topical and systemic thera-
pies. This in turn will provide needed 
therapeutic options for the millions of 
patients who suffer from chronic itch.
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